0 123

Cited 13 times in

Serum adipokine levels in rheumatoid arthritis patients and their contributions to the resistance to treatment.

Authors
 Kyoung Soo Kim  ;  Hyun Mi Choi  ;  Hye In Ji  ;  Ran Song  ;  Hyung In Yang  ;  Soo Kon Lee  ;  Myung Chul Yoo  ;  Yong Beom Park 
Citation
 Molecular Medicine Reports, Vol.9(1) : 255-260, 2014 
Journal Title
 Molecular Medicine Reports 
ISSN
 1791-2997 
Issue Date
2014
MeSH
Adipokines/blood* ; Adiponectin/blood ; Adult ; Aged ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/blood* ; Arthritis, Rheumatoid/drug therapy ; Drug Resistance, Neoplasm* ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Leptin/blood ; Male ; Middle Aged ; Nicotinamide Phosphoribosyltransferase/blood ; Resistin/blood ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Tumor Necrosis Factor-alpha/metabolism
Abstract
The aim of this study was to determine whether disease activity and the type of therapy differentially modulate serum adipokine levels in patients with rheumatoid arthritis (RA), and whether pre-therapy adipokine levels contribute to resistance to treatment. Fasting blood samples from 40 RA patients were obtained at baseline and six months following therapeutic treatment with disease-modifying antirheumatic drugs (DMARDs) and/or tumor necrosis factor (TNF)-α blockers. Serum levels of adiponectin, leptin, visfatin and resistin were measured by ELISA. Baseline adipokine levels did not exhibit a statistically significant difference when comparing patients with moderate and high disease activity, based on the disease activity score in 28 joints (DAS28). Of all the adipokines, only adiponectin was significantly increased in patients responding to DMARDs and/or TNF-α blocker therapy, based on the American College of Rheumatology 20% improvement criteria (ACR20) at six months (2,964±1,237 to 3,683±1,511 ng/ml, P<0.01). However, adiponectin levels in non-responders did not significantly increase (3,192±2,090 to 3,222±1,150 ng/ml). By contrast, there were no statistically significant changes in leptin, resistin or visfatin levels in either the responders or non-responders. Serum adipokine (adiponectin, leptin, visfatin, and resistin) levels in RA patients did not significantly change following therapy, with the exception of adiponectin. Adipokine levels may not contribute to therapeutic resistance to DMARDs and/or TNF-α blocking agents.
Full Text
http://www.spandidos-publications.com/10.3892/mmr.2013.1764
DOI
10.3892/mmr.2013.1764
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Park, Yong Beom(박용범)
Lee, Soo Kon(이수곤)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138736
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse